An interventional study of Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation in Refractive Surgery, sponsored by 59th Medical Wing. Recruiting at 1 site in United States. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by 59th Medical Wing · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a prospective randomized contralateral double-masked study. Each patient will be randomized as to which eye undergoes wave-front optimized (WFO) vs. wave-front guided (WFG) during Photorefractive keratectomy (PRK) or Laser-assisted in situ Keratomileusis (LASIK) surgery to determine which ablation profile provides the best visual outcome.
In 2015, the FDA approved a new laser ablation profile for performing laser corneal refractive surgery. Multiple sophisticated profiles have been developed in an attempt to optimize visual outcomes and reduce post-operative lower and higher-order optical aberrations. Among these include wave-front optimized (WFO) and wave-front guided (WFG) ablation profiles. The former compensated for corneal curvature to reduce spherical aberration and the latter, a more complicated ablation profile, was designed to minimize specific aberrations in an individual eye. Topographic profiles have also been used for over 17 years. These profiles consider the shape of the anterior corneal surface. The newest such topographic ablation profile, Contoura Vision, is a topography guided (TG) profile that, based on over 22,000 curvature data points captured using the VARIO Topolyzer, individualizes the ablation pattern. For comparison, WFO uses a patient's estimated average corneal curvature alone to create an ablation pattern. The addition of the VARIO Topolyzer adds a significant increase of pre-operative patient preparation. Anecdotally, between 1-3hrs of additional technician hours are required to prepare a patient for the Contoura Vision TG ablation profile.
This will be a prospective randomized contralateral double-masked study. Patients will undergo the same standard of care preoperative evaluation and education as any other patient not enrolled in the study. The physician performing surgery will choose either LASIK or PRK, taking into account patient preference, preoperative data and overall clinical picture, ultimately choosing which is best for the patient. If a patient qualifies for both, the patient may choose either LASIK or PRK. Each patient will be randomized as to which eye undergoes a WFO treatment vs Contoura. At the time of surgery the patient will be blinded as to which eye receives which treatment, but the surgical team will not be blinded as to which procedure is performed. Post-operatively, the ophthalmic technicians and optometrists responsible for postoperative examinations (measurement of visual acuity, refractions, transcription of PRO's) will be blinded as to which eye underwent Contoura vs WFO. While treatments will vary, both have the same safety profile. Both involve sophisticated lasers to change the shape of the cornea to achieve the desired outcome. The variance comes in the type of pattern the laser uses to treat each individual. All post-operative care will be standard of care with medications being the same as if the patient were not enrolled in the study. Post-operative evaluations will take place at postoperative day 1, week 1, month 1, month 3, and month 6.
All data collected will be standard pre- and post-operative ophthalmic refractive surgery measurements. This includes a standard medical history, especially to include prior eye surgeries or diseases. Pre-operative measurements include vision assessments, contrast sensitivity, pre- and post-dilation as well as keratometry and axial length measurements. The Contoura requires a separate set of data collection via the VARIO topolyzer. Intraoperative data collected will include variables such as actual treatment outcomes and laser settings. Post-operative measurements will consist of many of the same measurements as those obtained preoperatively including uncorrected and corrected visual acuity, and refractive measurements. A symptoms-based questionnaire specific to corrective eye surgery (PROWL) will be given to patients before and after surgery during routine follow-ups. Each PROWL is specific to an individual eye, not specific to the surgery performed in each eye (i.e. the same PROWL questionnaire will be used regardless of whether the patient underwent PRK or LASIK). All PROWL data will be compared pre- and post-operatively and will be stratified based on surgery.
59th Medical Wing is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
Device: Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation
Contralateral Randomize Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
Device: Wave-Front Optimized (WFO) ablation vs Topography-guided (TG) ablation
Patient will undergo PRK or LASIK using WFO ablation in one eye and TG ablation on contralateral eye
Post-operative refractive error
The Post-Operative sphere equivalent refractive error for eyes undergoing Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
Time frame: 6 months post-surgery
Post-operative Uncorrected Visual Acuity
The Post-Operative visual acuity for eyes undergoing Wave-Front Optimized (WFO) ablation vs Topography-guided ablation
Time frame: 6 months post-surgery
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Apr 2021 (actual). Primary completion is estimated for Dec 2026, 68 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
59th Medical Wing